Min menu


Latest News [LastPost]

Giving Corona patients blood thinning drugs immediately after admission to the hospital reduces complications

A new study found that giving blood thinners to patients with Corona the first 24 hours of hospitalization reduces the risk of death.

The researchers noted, according to a report by "medicalnewstoday," a 27% reduction in the risk of death for 30 days among patients who were treated with blood thinners.

Excessive blood clotting is a hallmark of some severe cases of corona, in May 2020, such high levels of clotting factors were found in the blood of patients with acute corona.

"We now know that these patients have incredibly viscous blood," said professor of hematology, Professor Beverly Hunt of the American Institutes of Health. It blocks some blood flow to the lungs.

The National Institutes of Health (NIH) recommends that everyone who is hospitalized for COVID-19 treatment, except for pregnant women, receive preventive anticoagulants.

Recently, a team of researchers in the United Kingdom and the United States published data from an observational, cohort study, and found that anticoagulant therapy was associated with significantly fewer deaths among people admitted to hospital due to Corona.

The researchers write: "Our results provide strong real-world evidence to support guidelines that recommend the use of preventive anticoagulation as a primary treatment for patients with Coronavirus upon admission to hospital."

Patient data

The team analyzed electronic health record data from veterans registered with the US Department of Veterans Affairs who were hospitalized with the Coronavirus between March 1 and July 31, 2020.

They collected information from 4,297 veterans who tested positive for coronavirus either 14 days before admission or within 14 days of hospitalization.

Subjects were excluded from the study if they had used anticoagulants - drugs that prevent excessive blood clotting - in the 30 days before admission to hospital, and people were also excluded if they were actively bleeding or had severe anemia.

The average age was 68 years, and most of the patients were men living in urban environments in the South, and among the patients, 45.1% were non-Hispanic blacks, 37.3% were non-Hispanic whites, and 11.8% were Hispanic.

Of the 4,297 patients in the study, 3,627 patients, or 84.4%, received preventive medications to prevent blood clotting within 24 hours of admission to the hospital. This drug is used to prevent blood clots in the veins or venous thromboembolism.

About 30.2% of the patients received subcutaneous heparin, a drug that prevents blood clots from forming, and 69.1% of the patients received a blood thinner called enoxaparin.

The 30-day mortality rate was lower among patients who received prophylactic drugs to prevent thrombosis than those who did not.

The report stated, that this study was observational, and without the results of a randomized clinical trial, it is difficult to confirm whether an anticoagulant treatment is effective or whether it is another variable, such as a patient characteristic or another treatment, that could affect the results.